Orlistat lowers blood pressure and reduces cardiovascular risk in obese people with inadequately controlled hypertension more effectively than does diet alone.
This is the result of a year-long prospective, randomized, double-blind, placebo multicenter trial undertaken by researchers from Rush University Hypertension/Clinical Research Center, Chicago, and other American centres including Roche Laboratories, New Jersey, United States.
All patients were given a 600 kcal deficient diet that provided 30 percent or less of the calories from fat. The patients were also randomized to receive orlistat or placebo. The patients taking orlistat showed greater weight loss than those on diet alone: reductions of 5.4 and 2.7 kg respectively.
Body mass also declined by a greater amount among those in the orlistat group compared to diet alone: reductions of 1.9 and 0.9 kg /m2 respectively. Furthermore, 46 percent of those taking orlistat and 23 percent of those in the placebo arm lost at least 5 percent of their body weight.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!